BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: González-hernández A, Condés-lara M, García-boll E, Villalón CM. An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 2021;17:179-99. [DOI: 10.1080/17425255.2021.1856366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Freitag FG. Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge. Front Pain Res (Lausanne) 2021;2:690683. [PMID: 35295521 DOI: 10.3389/fpain.2021.690683] [Reference Citation Analysis]
2 González-Hernández A, Marichal-Cancino BA, Villalón CM. The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opin Drug Metab Toxicol 2021;17:1223-35. [PMID: 34535065 DOI: 10.1080/17425255.2021.1982892] [Reference Citation Analysis]
3 Marichal-Cancino BA, González-Hernández A, Guerrero-Alba R, Medina-Santillán R, Villalón CM. A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Rev Neurother 2021;:1-16. [PMID: 34388955 DOI: 10.1080/14737175.2021.1968835] [Reference Citation Analysis]